neurodegeneration
Very little changed between July 21, 2020 and January 27, 2021. In both snapshots, CuraSen leads with the same framing: "Think, Again" and "Rethinking Neurodegeneration." The core belief looks stable: the company thinks standard assumptions in neurodegeneration are wrong or at least too limited, and that the field needs a different conceptual starting point. What changed is mostly the reading, not the doctrine. The 2021 language gives the same signal with slightly more interpretive weight because the paired slogans again present prevailing approaches as inadequate. But the underlying claim is still broad. There is no visible mechanism, disease model, target, or therapeutic thesis in the supplied text. That thinness matters. We can say CuraSen consistently positioned itself as a rethink-the-field company across this period. We cannot say, from these snapshots alone, what exactly it wanted to replace, how its scientific view differed from mainstream neurodegeneration research, or whether its internal hypothesis became more specific over time. The public stance is stable; the evidence for deeper belief change is sparse.